Management of Ocular Surface Inflammation with Persistent Epithelial Defects Using a Sutureless Human Amniotic Membrane Dehydrated Matrix: A Prospective Study Utilizing a Digital Ocular Surface Assessment Tool
Open Access
- 1 May 2024
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 18, 1467-1478
Abstract
Purpose: To report the outcomes of using a sutureless human amniotic membrane dehydrated matrix (HAMDM) in the management of a range of ocular surface conditions utilizing a digital ocular surface disease assessment tool. Methods: Two UK NHS Trusts — Queen Victoria Hospital Foundation Trust (East Grinstead and Maidstone) and Tunbridge Wells Trust (Kent) — prospectively treated patients with ocular surface disease with sutureless HAMDM. The patient cohort was assessed for resolution of epithelial defects, ocular surface inflammation, and best-corrected visual acuity pre- and posttreatment. Measurements of ocular surface inflammation and epithelial defect size were assessed using AOS digital imaging software, a validated tool for objective grading of bulbar conjunctival redness and measurement of corneal epithelial defects. Results: A total of 47 applications of sutureless HAMDM on 46 eyes of 46 patients (25 male, 21 female, age 9– 94 years) were assessed across various etiologies for an average of 24.0± 14.1 days. Patients with limbal stem-cell deficiency (n=17), persistent epithelial defects (n=16), neurotrophic corneal disease (n=7), filamentary keratitis (n=2), corneal erosion (n=1), corneal thinning (n=1), ocular surface inflammation (n=1), and traumatic corneal laceration (n=1) were included in the study. Across all patents, 63% of eyes showed complete healing of epithelial defects and 32.6% of eyes showed partial resolution. The average rate of healing (wound closure) was 0.36 mm2 per day across the overall patient cohort, and the rate of healing in cases with complete resolution of epithelial defects was 0.41 mm2 per day. Inflammation across all four quadrants of the ocular surface remained stable. Visual acuity across the patient cohort remained stable (61%) and improved in 26% of patients (0.06± 0.51 logMAR). Conclusion: Sutureless HAMDM application can be accomplished in just a few minutes and effectively treat a range of ocular surface disease in a clinical, nonsurgical setting. The AOS imaging software offered a quantitative methodology for measuring epithelial defect size and inflammation state.Keywords
This publication has 26 references indexed in Scilit:
- Ocular surface disease in thyroid eye disease: A narrative reviewThe Ocular Surface, 2022
- Evaluating a new objective grading software for conjunctival hyperaemiaContact Lens and Anterior Eye, 2020
- Blood derived eye drops for the treatment of cornea and ocular surface diseasesTransfusion and Apheresis Science, 2017
- TFOS DEWS II Definition and Classification ReportThe Ocular Surface, 2017
- Comparison of Amniotic Membrane Transplantation and Umbilical Cord Serum in Acute Ocular Chemical Burns: A Randomized Controlled TrialAmerican Journal of Ophthalmology, 2016
- Progress in corneal wound healingProgress in Retinal and Eye Research, 2015
- Management strategies for persistent epithelial defects of the corneaSaudi Journal of Ophthalmology, 2014
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- The amniotic membrane in ophthalmologySurvey of Ophthalmology, 2004
- Suppression of transforming growth factor-beta isoforms, TGF-? receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrixJournal of Cellular Physiology, 1999